Global Protein Kinase Inhibitor Market Overview:
Protein kinase is an enzyme that moves phosphate from ATP (Adenosine Triphosphate) to the protein structure and rearranges it. It controls a wide range of cell functions, including cell cycle, proliferation, apoptosis, and differentiation. In cancer, these cell processes are used to control a number of cell activities.A protein kinase inhibitor is a type of enzyme inhibitor that inhibits the activity of one or more protein kinases and is thought to be useful in preventing cancerous cell development. When the number of cancer patients grows, so does the need for new treatments. According to the World Health Organization (WHO), cancer took the lives of 9.6 million people worldwide in 2018. Furthermore, over the forecasted era, demand for kinase inhibitors is expected to be driven by increasing healthcare infrastructure in emerging economies and a focus on advanced cancer treatment.
- Increasing Number of Cancer Patients
- Rising Applications of Kinase Inhibitors in Cancer Therapies
- Rising Adoption of Advanced Technologies for Cancer Treatment
- Technological Advancement in the Healthcare Industry
- Stringent Government Regulations Regarding Approval Procedure
- High Cost of Cancer Treatment
- Rise in Number of Clinical Trials
- Increasing Demand from the Developing Economies
- Lack of Advanced Healthcare Infrastructure in the Low and Middle Income Group Countries
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Roche Holding AG (Switzerland), Novartis (Switzerland), AstraZeneca (United Kingdom), Bayer (Germany), Pfizer (United States), GlaxoSmithKline (United Kingdom), Bristol-Myers Squibb (United States), Cytrx Corporation (United States), Eisai Inc. (United States) and Merck Serono SA (Switzerland). Additionally, following companies can also be profiled that are part of our coverage like Eton Bioscience Inc. (United States) and Inhibikase Therapeutics, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Protein Kinase Inhibitor market by 2026. Considering Market by End Use, the sub-segment i.e. Therapeutic will boost the Protein Kinase Inhibitor market. Considering Market by End User, the sub-segment i.e. Pharmaceutical companies will boost the Protein Kinase Inhibitor market.
“The US FDA has approved 48 small molecule protein kinase inhibitors, nearly all of which are orally effective with the exceptions of netarsudil (which is given as an eye drop) and temsirolimus (which is given intravenously). Of the 48 approved drugs, the majority (25) target receptor protein-tyrosine kinases, ten target non-receptor protein-tyrosine kinases, and 13 target protein-serine/threonine protein kinases.”
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Protein Kinase Inhibitor market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Protein Kinase Inhibitor market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Research Organizations, Potential Investors, Government Regulatory Authorities, Research and Development Companies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.